Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05257083




Registration number
NCT05257083
Ethics application status
Date submitted
16/02/2022
Date registered
25/02/2022
Date last updated
6/06/2024

Titles & IDs
Public title
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Scientific title
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Secondary ID [1] 0 0
2021-003284-10
Secondary ID [2] 0 0
EMN28/68284528MMY3005
Universal Trial Number (UTN)
Trial acronym
CARTITUDE-6
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daratumumab
Treatment: Drugs - Bortezomib
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Cilta-cel
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Fludarabine

Active Comparator: Arm A: DVRd + ASCT+DVRd (Standard Therapy) - Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 4 induction cycles. Followed by ASCT and 2 cycles of DVRd consolidation, and lenalidomide maintenance therapy for 2 years
Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.
Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6. Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6. Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.
Each cycle will consist 28 days.
Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years

Experimental: Arm B: DVRd followed by Ciltacabtagene Autoleucel - Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 6 induction cycles.
Participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg), followed by lenalidomide post CAR-T cell therapy for 2 years
Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.
Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6.
Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6.
Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.
Each cycle will consist of 28 days.
Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years


Treatment: Drugs: Daratumumab
Daratumumab will be administered SC.

Treatment: Drugs: Bortezomib
Bortezomib will be administered SC.

Treatment: Drugs: Lenalidomide
Lenalidomide will be administered orally.

Treatment: Drugs: Dexamethasone
Dexamethasone will be administered orally.

Treatment: Drugs: Cilta-cel
Cilta-cel will be administered intravenously

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide will be administered intravenously.

Treatment: Drugs: Fludarabine
Fludarabine will be administered intravenously.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression free survival (PFS)
Timepoint [1] 0 0
up to 10 years ( or 300 PFS events)
Primary outcome [2] 0 0
Sustained MRD-negative CR
Timepoint [2] 0 0
up to 24 months
Secondary outcome [1] 0 0
Overall Response (OR)
Timepoint [1] 0 0
up to 17 years
Secondary outcome [2] 0 0
Complete Response (CR) or better status
Timepoint [2] 0 0
up to 17 years
Secondary outcome [3] 0 0
Overall Minimal Residual Disease (MRD) -negative CR
Timepoint [3] 0 0
up to 17 years
Secondary outcome [4] 0 0
Time to subsequent antimyeloma therapy
Timepoint [4] 0 0
up to 17 years
Secondary outcome [5] 0 0
Progression Free Survival on Next-line Therapy (PFS2)
Timepoint [5] 0 0
up to 17 years
Secondary outcome [6] 0 0
Overall Survival (OS)
Timepoint [6] 0 0
up to 17 years
Secondary outcome [7] 0 0
Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
Timepoint [7] 0 0
up to 17 years
Secondary outcome [8] 0 0
Change from Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Score
Timepoint [8] 0 0
up to 17 years
Secondary outcome [9] 0 0
Change from Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Scor
Timepoint [9] 0 0
up to 17 years
Secondary outcome [10] 0 0
Change from Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
Timepoint [10] 0 0
up to 17 years
Secondary outcome [11] 0 0
Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Timepoint [11] 0 0
up to 280 days

Eligibility
Key inclusion criteria
- Participants with documented NDMM according to IMWG diagnostic criteria, for whom
high-dose therapy and ASCT are part of the intended initial treatment plan.

- Measurable disease, as assessed by central laboratory, at screening as defined by any
of the following:

1. Serum monoclonal paraprotein (M-protein) level =1.0 g/dL or urine M-protein level
=200 mg/24 hours; or

2. Light chain MM without measurable disease in serum or urine: serum Ig free-light
chain (FLC) =10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.

- ECOG performance status of grade 0 or 1

- Clinical laboratory values within prespecified range.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior treatment with CAR-T therapy directed at any target.

- Any prior BCMA target therapy.

- Any prior therapy for MM or smoldering myeloma other than a short course of
corticosteroids

- Received a strong cytochrome P450 (CYP)3A4 inducer within 5 half-lives prior to
randomization

- Received or plans to receive any live, attenuated vaccine (except for COVID-19
vaccines) within 4 weeks prior to randomization.

- Known active, or prior history of central nervous system (CNS) involvement or clinical
signs of meningeal involvement of MM

- Stroke or seizure within 6 months of signing Informed Consent Form (ICF)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/10/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2040
Actual
Sample size
Target
750
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [3] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [4] 0 0
Royal Brisbane and Womens Hospital - Herston
Recruitment hospital [5] 0 0
Alfred Health - Melbourne
Recruitment hospital [6] 0 0
Austin Hospital - Melbourne
Recruitment hospital [7] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [8] 0 0
St. Vincent's Hospital - Melbourne
Recruitment hospital [9] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [10] 0 0
Calvary Mater Newcastle Hospital - Waratah
Recruitment hospital [11] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Brisbane
Recruitment postcode(s) [3] 0 0
- Camperdown
Recruitment postcode(s) [4] 0 0
- Herston
Recruitment postcode(s) [5] 0 0
- Melbourne
Recruitment postcode(s) [6] 0 0
- Murdoch
Recruitment postcode(s) [7] 0 0
- Waratah
Recruitment postcode(s) [8] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
Belgium
State/province [20] 0 0
Antwerpen
Country [21] 0 0
Belgium
State/province [21] 0 0
Gent
Country [22] 0 0
Belgium
State/province [22] 0 0
Leuven
Country [23] 0 0
Canada
State/province [23] 0 0
Calgary
Country [24] 0 0
Canada
State/province [24] 0 0
Edmonton
Country [25] 0 0
Canada
State/province [25] 0 0
Hamilton
Country [26] 0 0
Canada
State/province [26] 0 0
Montréal
Country [27] 0 0
Canada
State/province [27] 0 0
Ottawa
Country [28] 0 0
Canada
State/province [28] 0 0
Québec
Country [29] 0 0
Canada
State/province [29] 0 0
Toronto
Country [30] 0 0
Canada
State/province [30] 0 0
Vancouver
Country [31] 0 0
Czechia
State/province [31] 0 0
Brno
Country [32] 0 0
Czechia
State/province [32] 0 0
Králová
Country [33] 0 0
Czechia
State/province [33] 0 0
Ostrava
Country [34] 0 0
Czechia
State/province [34] 0 0
Plzen
Country [35] 0 0
Czechia
State/province [35] 0 0
Prague
Country [36] 0 0
France
State/province [36] 0 0
Lille
Country [37] 0 0
France
State/province [37] 0 0
Lyon
Country [38] 0 0
France
State/province [38] 0 0
Nantes
Country [39] 0 0
France
State/province [39] 0 0
Paris
Country [40] 0 0
France
State/province [40] 0 0
Poitiers
Country [41] 0 0
France
State/province [41] 0 0
Saint-Louis
Country [42] 0 0
France
State/province [42] 0 0
Toulouse
Country [43] 0 0
Germany
State/province [43] 0 0
Cologne
Country [44] 0 0
Germany
State/province [44] 0 0
Dresden
Country [45] 0 0
Germany
State/province [45] 0 0
Hamburg
Country [46] 0 0
Germany
State/province [46] 0 0
Heidelberg
Country [47] 0 0
Germany
State/province [47] 0 0
Leipzig
Country [48] 0 0
Germany
State/province [48] 0 0
Tübingen
Country [49] 0 0
Germany
State/province [49] 0 0
Würzburg
Country [50] 0 0
Greece
State/province [50] 0 0
Athens
Country [51] 0 0
Greece
State/province [51] 0 0
Thessaloníki
Country [52] 0 0
Israel
State/province [52] 0 0
Jerusalem
Country [53] 0 0
Israel
State/province [53] 0 0
Ramat Gan
Country [54] 0 0
Israel
State/province [54] 0 0
Tel Aviv
Country [55] 0 0
Italy
State/province [55] 0 0
Ancona
Country [56] 0 0
Italy
State/province [56] 0 0
Bologna
Country [57] 0 0
Italy
State/province [57] 0 0
Genova
Country [58] 0 0
Italy
State/province [58] 0 0
Milan
Country [59] 0 0
Italy
State/province [59] 0 0
Roma
Country [60] 0 0
Italy
State/province [60] 0 0
Turin
Country [61] 0 0
Japan
State/province [61] 0 0
Bunkyo-Ku
Country [62] 0 0
Japan
State/province [62] 0 0
Fukuoka
Country [63] 0 0
Japan
State/province [63] 0 0
Hokkaido
Country [64] 0 0
Japan
State/province [64] 0 0
Hyogo
Country [65] 0 0
Japan
State/province [65] 0 0
Kanazawa
Country [66] 0 0
Japan
State/province [66] 0 0
Nagoya
Country [67] 0 0
Japan
State/province [67] 0 0
Okayama
Country [68] 0 0
Japan
State/province [68] 0 0
Osaka
Country [69] 0 0
Japan
State/province [69] 0 0
Shibuya
Country [70] 0 0
Japan
State/province [70] 0 0
Shinjuku-Ku
Country [71] 0 0
Japan
State/province [71] 0 0
Tohoku
Country [72] 0 0
Netherlands
State/province [72] 0 0
Amsterdam
Country [73] 0 0
Netherlands
State/province [73] 0 0
Groningen
Country [74] 0 0
Netherlands
State/province [74] 0 0
Nijmegen
Country [75] 0 0
Netherlands
State/province [75] 0 0
Rotterdam
Country [76] 0 0
Netherlands
State/province [76] 0 0
Utrecht
Country [77] 0 0
Norway
State/province [77] 0 0
Oslo
Country [78] 0 0
Spain
State/province [78] 0 0
Badalona
Country [79] 0 0
Spain
State/province [79] 0 0
Barcelona
Country [80] 0 0
Spain
State/province [80] 0 0
Madrid
Country [81] 0 0
Spain
State/province [81] 0 0
Pamplona
Country [82] 0 0
Spain
State/province [82] 0 0
Salamanca
Country [83] 0 0
Spain
State/province [83] 0 0
Santiago De Compostela
Country [84] 0 0
Spain
State/province [84] 0 0
Sevilla
Country [85] 0 0
Spain
State/province [85] 0 0
Valencia
Country [86] 0 0
Sweden
State/province [86] 0 0
Göteborg
Country [87] 0 0
Sweden
State/province [87] 0 0
Linköping
Country [88] 0 0
Sweden
State/province [88] 0 0
Lund
Country [89] 0 0
Sweden
State/province [89] 0 0
Uppsala
Country [90] 0 0
Switzerland
State/province [90] 0 0
Basel
Country [91] 0 0
Switzerland
State/province [91] 0 0
Bern
Country [92] 0 0
Switzerland
State/province [92] 0 0
Lausanne
Country [93] 0 0
Switzerland
State/province [93] 0 0
Zürich
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Birmingham
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Cardiff
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Leeds

Funding & Sponsors
Primary sponsor type
Other
Name
Stichting European Myeloma Network
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Janssen Research & Development, LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide
and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,
Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant
(ASCT) in newly diagnosed multiple myeloma patients.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05257083
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Sarah Lonergan
Address 0 0
Country 0 0
Phone 0 0
+31 107033123
Fax 0 0
Email 0 0
sarah.lonergan@emn.life
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05257083